Open Science for Health: Shaping the New Framework Programme

by JAUME VIDAL, Policy Advisor - Europe Health Action International (HAI) and Commons Network were joined last week in a packed room at the European Parliament by European Union lawmakers, policy-makers and other civil society groups to debate the challenges and opportunities ahead for the medical research and development (R&D) system. Open Science for Health [...]

EU-Mercosur Trade Agreement: A bad deal for transparency, policy coherence and access to medicines

by JAUME VIDAL, Policy Advisor – Europe

The European Union (EU) and Mercosur have been negotiating a free trade agreement for the last 16 years, with talks picking up pace in the last 15 months. Negotiations are now nearing completion and there are increasing concerns among public health advocates, patient and consumer organisations,

New Dutch Government Must Ensure Transparency to Control Medicine Prices

by JAUME VIDAL After almost seven months of negotiations, The Netherlands has formed a new coalition government, which recently outlined its priorities and main policy objectives in its Coalition Agreement. On the whole, it’s good news from an access to medicines perspective—particularly pricing and procurement, which remain high on the government’s priority list. Some of [...]

START TYPING AND PRESS ENTER TO SEARCH